In 2010, Qualitest joined Endo International plc – a global specialty healthcare company focused on improving patients’ lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic and device products through its operating companies. Endo has global headquarters in Dublin, Ireland and US headquarters in Malvern, PA.
DAVA Pharmaceuticals, Inc. became part of Qualitest Pharmaceuticals, an Endo International plc company.
Boca Pharmacal was a specialty generics company with a unique generics product portfolio and complementary pipeline that builds on Qualitest’s strength in controlled substances.
In May, 2015 Endo International plc (NASDAQ: ENDP) (TSX: ENL) and Par Pharmaceutical Holdings, Inc. announced that they have entered into a definitive agreement under which Endo will acquire privately held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt. Qualitest subsequently merged into Par in July 2016 which effectively dissolved Qualitest as a company.
In 2015, over one hundred women have filed legal action against the company.